During the most recent 90-day period, previous to the date of this filing, there have been 35 insider transactions from the activities of 7 different insiders all of which have been purchases and resulted in the acquisition of 4,435,250 company shares. In the preceding 90-day window of time, there were 18 transactions from 2 insiders that resulted in the net acquisition of 897,232 shares.
This is less than the average level of insider transactions in the 150-company Pharmaceuticals peer group over the last 90-day period. Within the peer group activity averaged 36.7 transactions per company, and disposition of 6,750 shares on average.
SEC Story Link http://www.sec.gov/Archives/edgar/data/944809/000120919119042302/xslF345X03/doc4.xml
|Cree, ABB Team Up to Introduce Silicon Carbide Techn...|
|T-Mobile US Chief Executive Legere Confirms He's Sta...|
|Sector Update: Energy|
|Esperion Therapeutics' Pooled Analyses of Bempedoic ...|
|Axovant Wins Orphan Drug Designation for GM1 Ganglio...|